image credit- shutterstock
US-based GEM Global Yield LLC SCS has executed a Share Purchase Agreement (SPA) with the existing shareholders of Taiwan-listed Senhwa Biosciences Inc., under which GEM has committed up to NT$500 million (approximately $15.5 million) to purchase shares in the company over the next 3-5 years.
Taiwan's biotechnology industry continues to attract increasing international attention through innovative oncology research, expanding global clinical collaborations and the adoption of artificial intelligence to accelerate drug discovery and clinical development.
Under the framework of the SPA, the equity commitment from GEM provides additional financial flexibility and is expected to support continued investment in Senhwa's clinical pipeline, potential in-licensing opportunities, and AI-enabled pipeline prioritisation and expansion.
The company's lead assets are CX-5461 (pidnarulex) and CX-4945 (silmitasertib), two investigational oncology therapies being studied across multiple cancer indications. Senhwa has established research and development collaborations with organisations including the US National Cancer Institute (NCI), BeOne Medicines, and CellType, a Y Combinator-backed artificial intelligence company whose platform incorporates technology developed with Google DeepMind.
CX-5461 is currently involved in studies sponsored by the NCI and Senhwa expects to initiate a clinical study combining the drug with BeOne Medicines' PD-1 antibody, tislelizumab. CX-4945 is being investigated across several oncology indications, including cholangiocarcinoma, CNS tumours and pediatric cancers. In addition, preclinical studies are evaluating both compounds as potential combination partners for RAS-targeted therapies, although their clinical utility in this setting has not yet been established.
